Atacicept is a recombinant fusion protein that binds to and inhibits the activity of BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand).
FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting ...
Early diagnosis of pulmonary arterial hypertension improves five-year survival by 42%, compared with delayed diagnosis, a ...
Background Annually, 4% of the global population undergoes non-cardiac surgery, with 30% of those patients having at least ...
News-Medical.Net on MSN
A single immune protein may help explain why kidney and heart disease often develop together
This review synthesizes clinical, genetic, and mechanistic evidence showing that suPAR and related uPAR fragments are ...
Protein is not the problem—excess and imbalance are. Kidneys are remarkably resilient, but they function best when demands are reasonable and consistent. As protein supplements become more common, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback